Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

Posts tagged ‘CD20-TCB’

Lugano: This post offers a rundown and synopsis of a wide variety of lymphoma trials across different subsets coming out of the 15th International Conference on Malignant Lymphoma (iCML) being in Lugano, Switzerland this week.

Lugano is a glorious place to hold a meeting!

The meeting is held every two years on odd years, usually after the EHA conference.

As such, this review may well turn out to be a useful reference point for later offering background and context for the upcoming ASH meeting in December, since there will likely be additional trial updates and readouts in Orlando.

Some of the updates on the early phase 1/2 trials reference preclinical posters from old AACR meetings circa 2012–2014, which is why the Gems from the Poster Hall series can often turn out to be useful predictors of later clinical trials performance!

There’s a lot to cover and discuss this year and some intriguing developments under the radar…

To learn more and get a heads up on our latest oncology insights and conference analysis, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

River Rhine, Mainz

Mainz, Germany: We’re back for Day 2 highlights from the 2019 Association for Cancer Immunotherapy (CIMT) annual meeting with a look at some insights emerging from some academic and industry talks, as well as gems emerging from the poster halls.

Much attention is focused on cancer immunotherapy clinical data, yet it’s also important to watch out for new developments.

These can take many different forms such as what are companies doing to meet those challenges with novel therapeutics, as well as understanding more detail about immune mechanisms, including evasion and escape as well as defining phenotypes based on different immune cell populations.

As we head into ASCO, let’s not forget that there’s some important learnings to be had elsewhere in the world before we get there…

To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Gaudi’s Casa Milà/La Pedrera, Barcelona

Barcelona: There’s a lot of choice when it comes to cancer immunotherapy conferences, but an event that caught our attention this year as one that merited coverage is the European Association for Cancer Research (EACR) meeting, Defense is the Best Attack – Immuno-Oncology Breakthroughs taking place in Barcelona this week.

The conference is being held in the basement of La Pedrera, Gaudi’s famous Casa Milà modernist building in Barcelona (right).

It’s such an old building that you’re actually forbidden to plug in any phones or computers to charge them for fear of over-loading the electrics, so it’s an event that requires you to be fully charged upfront!

What were some of the highlights from Day 1?  There were some key data and concepts being presented that will grab folks involved in cancer research…

To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Free Email Updates
Subscribe to new post alerts, offers, and additional content!
We respect your privacy and do not sell emails. Unsubscribe at any time.
error: Content is protected !!